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Purpose: Robo4, a member of the roundabout (Robo) family, acts as a neuronal guidance receptor and plays some role
in vasculogenesis and angiogenesis. This study investigated the effect of Robo4 on the formation of fibrovascular
membranes (FVMs) from patients with proliferative diabetic retinopathy and its roles in choroid–retina endothelial (RF/
6A) and human retinal pigment epithelial (RPE) cells.
Methods: RT–PCR and immunohistochemistry were used to determine the levels of mRNA and the presence and
distribution of Robo4 in FVMs. Small interfering RNA (siRNA) technology was used to knock down Robo4 expression
and to study its effects on RF/6A and RPE cells in vitro. Cell proliferation, migration, spreading, cycling, and apoptosis
were assessed with MTT assay, Boyden chamber assay, immunocytochemistry, and flow cytometry. Tube formation by
RF/6A on Matrigel was also analyzed.
Results: The level of Robo4 mRNA was high in FVMs. Robo4 was expressed in the vessels and fibrous-like tissue co-
immunostained for CD31 and GFAP, respectively. Robo4 siRNA knockdown inhibited cell proliferation and migration.
Tube formation by RF/6A cells was also disturbed. Under hypoxic conditions, more apoptotic cells were evident among
the knockdown cells than among the control cells (p<0.01).
Conclusions: Robo4 may play a role in the formation of FVMs. Silencing the expression of Robo4 in RF/6A and RPE
cells inhibited their proliferation and reduced their tolerance of hypoxic conditions, suggesting physiologic functions of
Robo4 in the cells of the retina.
Retinal angiogenesis and choroid angiogenesis are major
causes of vision loss in a variety of clinical conditions, such
as  retinopathy  of  prematurity  (ROP),  age-related  macular
degeneration (AMD), and diabetic retinopathy [1,2]. Many
problems associated with pathological angiogenesis do not
arise directly from the growth of new blood vessels but from
abnormalities in the newly formed microvasculature, such as
increased permeability. Current treatments attempt to abolish
these new vessels and/or to prevent their formation. However,
a  more  effective  intervention  may  be  to  stabilize  these
abnormal vessels or cause them to mature [3,4].
Robo4 is a member of the roundabout (Robo) family,
which contains guidance receptors involved in neurogenesis,
which mediate a repulsive signal signal that keeps navigating
axons from crossing the midline inappropriately during the
process of axonal guidance. The Robo family contains large
transmembrane receptors, comprising Robo1, Robo2, Robo3,
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and  Robo4.  Robo4  is  also  known  as  “magic  roundabout”
(MRB).  All  known  Robo  family  members  have  a  large
extracellular domain composed of five immunoglobulin and
three  fibronectin  motifs,  except  Robo4,  the  extracellular
domain of which consists of only two immunoglobulins and
two fibronectin motifs, and is quite different from the other
Robos. Robo4 was first identified as an endothelial-specific
member of the roundabout family [5,6] and was later shown
by Park et al. [7] to be differentially expressed in activin-like
kinase-1−/− mice, which exhibit impaired angiogenesis during
development.  In  silico  and  in  vitro  expression  analyses
indicated  that  Robo4  is  highly  endothelial  specific  and  is
strongly upregulated in the vessels of tumors in the brain,
colon,  and  bladder  [5,8].  In  zebrafish,  the  knockdown  or
overexpression of Robo4 resulted in the temporal and spatial
disruption of embryonic vascular development [9], whereas
in Robo4-knockout mice, the patterning of the intersomitic
and cephalic vessels was normal during early embryogenesis
[10],  indicating  that  Robo4  may  have  different  roles  in
different species. The expression patterns of Robo4 differ
across species. In zebrafish, Robo4 is expressed in both neural
tissues  and  the  vascular  system,  whereas  in  mice,  Robo4
Molecular Vision 2009; 15:1057-1069 <http://www.molvis.org/molvis/v15/a112>
Received 8 March 2009 | Accepted 20 May 2009 | Published 29 May 2009
© 2009 Molecular Vision
1057expression is confined to vessels. Murine embryonic Robo4
expression  shows  a  dynamic  pattern  within  vessels,  with
expression starting in the larger axial vessels and intersomitic
vessels  in  the  earlier  embryonic  stages,  but  changing  to
intersomitic vessel and capillary expression in later stages.
However, in the adult, Robo4 is highly expressed in complex
and well organized vascular networks, such as those in the
lung,  liver,  and  heart.  The  expression  patterns  of  Robo4
observed in embryonic and adult tissues suggest that it may
be  important  in  guiding  and  maintaining  the  highly
reproducible vascular patterning (i.e., the formation of tubular
structures) [7]. More recently, defects have been identified in
the  vascular  integrity  of  Robo4-knockout  mice,  which
exacerbate  the  pathological  conditions  associated  with
vascular  leakage,  suggesting  that  Robo4  provides  a  tonic
signal that stabilizes the retinal blood vessels [10]. Robo4
expression has been detected in endothelial cells but not in
nonendothelial cell lines, such as fibroblasts and endometrial
stoma cells [5,11].
RF/6A, a choroid–retinal endothelial cell line derived
from a rhesus macaque fetus, is evolutionarily close to retinal
cells  derived  from  humans.  It  has  been  identified  as  of
endothelial  origin  based  on  cellular  morphology  and
immunodiffusion  and  is  widely  used  in  studies  of  retinal
endothelial cells [12-15].
The  retinal  pigment  epithelium  (RPE)  has  important
functions  in  both  the  normal  eye  and  under  pathological
conditions.  Recently,  vascular  endothelial  growth  factor
(VEGF) and its receptor, VEGFR2, have been shown to be
highly  expressed  by  the  RPE  and  in  the  underlying
mesenchyme,  respectively,  at  the  time  of  choriocapillary
formation in both humans [16] and rodents [17,18].
Although  there  have  been  many  studies  of  Robo4
expression,  the  biologic  function  of  Robo4  in  the  retinal
vascular  disease  is  yet  to  be  demonstrated.  This  study
characterizes  the  expression  of  Robo4  in  fibrovascular
membranes (FVMs) and explores in vitro the role of Robo4
in the retina using two important retinal cell lines, RF/6A and
RPE.
METHODS
Tissue  sample:  This  study  protocol  was  approved  by  the
Ethics Committee of the Peking University, and informed
consent was obtained from all patients according to the World
Medical  Association  Declaration  of  Helsinki.  The  FVMs
specimens  were  surgically  removed  from  the  eyes  of  11
patients  with  type  2  diabetes  with  proliferative  diabetic
retinopathy (PDR; 11 eyes) undergoing pars plana vitrectomy
with membrane peeling. The patients were six male and five
female. Ages ranged between 50 and 75 years (mean age
64.4±11.6). Their duration of diabetes ranged between 6 and
20 years(mean duration 12.2±6.7 years). Six FVM specimens
obtained  immediately  were  put  into  liquid  nitrogen  were
processed for reverse transcription-polymerase chain reaction
(RT–PCR) analysis. The remaining five FVM specimens were
fixed in a test tube containing 4% paraformaldehyde (PFA)
and subsequently embedded in optimum cutting temperature
compound (OCT) for immunohistochemistry.
Cell culture and reagents: RF/6A cells (CRL-1780 cell line)
and human RPE cells (D407 cell line) were obtained from the
American  Tissue  Culture  Collection  (Manassas,  VA)  and
were cultured in Dulbecco’s Modified Eagle Media (DMEM)
with 10% fetal bovine serum (FBS, Gibco, Invitrogen, Grand
island, NY), 100 units/ml penicillin, 100 µg/ml streptomycin
(Sigma, St. Louis, MO) at 37 °C under 5% CO2, and 95%
humidified air. Before hypoxia, the media was replaced with
DMEM  free  of  serum.  The  cells  were  then  incubated
overnight and perfused with 1% O2, 94% N2, and 5% CO2 in
TABLE 1. SIRNA SYBTYPE OLIGONUCLEOTIDE SEQUENCES.
siRNA subtype Oligonucleotide primers (5′-3′)
Robo4 F: CCUCAGAGUUCACGGACAUTT
R: AUGUCCGUGAACUCUGAGGTT
NS F: UUCUCCGAACGUGUCACGUTT
R: ACGUGACACGUUCGGAGAATT
TABLE 2. GENE SUBTYPE OLIGONUCLEOTIDE PRIMERS.
Gene subtype Oligonucleotide primers (5′-3′) Size (bp)
GAPDH F: GAGTCCACTGGCGTCTTCAC 120
R: GTTCACACCCATGACGAACA
RF/6A Robo4 F: CTGGTTGGAAGACAT GGA 93
R: ACTTCTCTGGGAAGAGATCC
human Robo4 F: CCCTGTGCTTGGAACTCAGTG 102
R: CGCTGATGTACCCATAGGTGG
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1058a CO2 incubator for 24 h [19]. Hiperfect Transfection Reagent
was purchased from Qiagen (Hilden, Germany).
Small interfering RNA and transfection assays: The Robo4
(GenBank  NM019055)-specific  siRNAs  were  chemically
synthesized (Table 1). RF/6A and RPE cells were transfected
with  siRNA  by  using  Hiperfect  Transfection  Reagent
according  to  the  manufacturer’s  instructions.  Briefly,  the
original  stock  of  the  siRNA  was  suspended  in  siRNA
suspension  buffer  (Qiagen,  Hilden,  Germany,  Cat  No.
301799)  provided  by  the  manufacturer.  The  resulting
suspension was aliquoted in the required amounts for each
experiment and stored at −20 °C until it was ready to use. On
the day of transfection, cells were seeded in plates at the
recommended density. For example, 24-well plate: 2–8×104;
96  well  plate:  0.5–3×104.  The  siRNA  was  then  gently
introduced into the cells by mixing with the required amount
of Hiperfect Transfection Reagent. In our study, the final
concentration of siRNA was 10 nm. Nonsilencing siRNA was
used  to control for any effects of the transfection reagent and
siRNA. The  assays described  here in vitro were performed
48 h post-transfection.
RNA isolation: Total RNA was isolated with Trizol reagent
(Invitrogen, Carlsbad, CA) according to the manufacturer’s
instructions. After being washed with 75% ethanol, the final
RNA  extracts  were  eluted  in  a  20  µl  volume  of  distilled
Diethyl  Pyrocarbonate  (DEPC)-treated  water.  The
concentration  and  purity  of  RNA  were  measured  by
spectrophotometer.  All  the  RNA  preparations  had  an
OD260:OD280 ratio of 1.9–2.0.
RT–PCR and Real-time PCR: Two μg of retinal RNAwas
converted into cDNA in a total reaction volume of 25 ml,
containing 1 mg Oligo (dT) 15, 5 ml M-MLV 5×Reaction
Buffer, 1.25 ml dNTPs, 25 units Recombinant RNasin RNase
Inhibitor, and 200 Units of M-MLV Reverse Transcriptase.
The mixture was incubated for 60 min at 42 °C and reverse
transcription was terminated by incubation at 95 °C for 5 min
[20].  The  single-stranded  cDNA  was  amplified  in  a
Figure  1.  RT–PCR  analysis  of  Robo4  in  FVMs  derived  from
proliferative diabetic retinopathy patients. After 35 cycles, 10 μl each
sample  was  separated  electrophoretically  through  a  1.5%  Tris–
acetate–EDTA agarose gel, and an expected product at 102 bp for
Robo4 were stained with ethidium bromide. 1–6 was on behalf of 6
patients.
primers  for  glyceraldehydes  phosphate  dehydrogenase
(GAPDH) or for RF/6A Robo4, or for human Robo4 (Table
2). The real-time PCR assays were performed according to the
manufacturer’s instructions. The real-time PCR assays were
performed using IQ Supermix (Bio-Rad, Hercules, CA) with
each 20 μl reaction mixture containing 2 µl cDNA, 7.2 µl
sterilized water, 10 µl SYBR Green Real-time PCR Master
Mix (2×), and 0.8 µl of each primer (10 µM). Amplification
was performed in 96-well plates on an iCycler iQ real-time
detection  system  (Bio-Rad).  Thermo-cycling  conditions
consisted of 3 min at 95 °C for activating the iTaq DNA
polymerase and 35 cycles of a 20 s, 95 °C denaturation step,
a 15 s 63 °C annealing step, and a 15 s 72 °C extension step
Robo4 was normalized to GAPDH expression and calculated
using the equation: Fold change=2−ΔΔct.
Western  blot  analysis:  Cells  were  washed  with  ice-cold
phosphate-buffered saline (PBS;, 4 °C, 8.00 g NaCl, 0.20 g
KCl, 0.24 g KH2PO4 and 1.44 g Na2HPO4 in 1 l distilled water,
pH 7.4) for three times every 5 min at room temperature, and
prepared using the protein extraction kit and protease inhibitor
kit (Pierce, Rockford, IL) and cleared by centrifugation at
12,000x g at 4 °C. The supernatant was collected and the
protein content of each lysate was measured using a BCA
Protein Assay Kit (Tianlai shengwu jishu, Tianlai, China)
according to the manufacturer’s instructions. Equal amounts
20  μg  of  protein  were  loaded  and  analyzed  by
immunoblotting.  Proteins  were  visualized  with  enhanced
chemiluminescence  western  blotting  detection  reagents
(Pierce) according to the manufacturer’s recommendations.
Band densities of Robo4 proteins were normalized to each β-
actin internal control. Western blots were repeated three times
and qualitatively similar results were obtained.
Immunohistochemistry: Membrane tissues were snap-frozen
and 6 μm sections were cut. Thawed tissue sections were air
dried, placed in 4% paraformaldehyde (PFA) for 20 min for
fixing, washed with PBS, and blocked with 10% normal goat
serum for 1 h at 37 °C. Next, 1:100 anti-Robo4 polyclonal
antibody (Abcam, Cambridge, UK, Cat No.ab10547) with
1:100 anti-GFAP or anti-CD31 (Santa Cruz, Santa Cruz, CA)
was  applied  to  the  tissue  sections  at  4  °C  overnight  and
incubated  for  1  h  at  37  °C  with  1:100  fluorescein
isothiocyanate  (FITC)  and  tetramethyl  rhodamine
isothiocyanate  (TRITC)-conjugated  mouse  anti-rabbit  and
mouse  anti-goat  secondary  antibodies  (Santa  Cruz),
respectively. Following incubation, the slides were washed
and  cell  nuclei  were  stained  with  4’,  6’-diamino-2-
phenylindole  (DAPI).  Images  were  acquired  with  a
fluorescence microscope equipped with a digital camera. For
each of the immunostaining procedures, negative controls
included omission of the primary antibody and use of an
irrelevant polyclonal or isotype-matched monoclonal primary
antibody; in all cases, negative controls showed only faint,
insignificant staining.
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polymerase  chain  reaction(PCR),  using  sequence-specificImmunocytochemistry: RF/6A and RPE cells (1×104) grown
on glass coverslips were washed with PBS three times every
5 min at room temperature and fixed with 4% PFA in PBS and
then permeabilized with 0.1% Triton X-100 before they were
blocked with 10% goat serum. The slides were incubated with
Robo4 antibody at 4 °C overnight and then were washed with
PBS and incubated for 1 h at 37 °C with TRITC conjugated
mouse  anti-rabbit  secondary  antibody.  Following  the
incubation, slides were washed and cell nuclei were stained
with  DAPI.  Images  were  acquired  with  a  fluorescence
microscope  equipped  with  a  digital  camera  (Leica
Microsystems  GmbH,  Wetzlar,  Germany).  In  each  case,
preimmune  IgG  and  secondary  control  incubations  were
conducted to determine specificity of staining.
Cytotoxicity assay and cell proliferation assay: Transfection
reagent- and siRNA-induced cytotocity was deternmined by
a  3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide  assay  assay  (MTT)  in  accordance  with  the
manufacture’s instruction. In brief, each of the growing cell
lines were plated at 1×104 per well in 96 well plates. Three
controls  were  used:  one  without  transfection,  one  with
transfection  reagent,  and  one  with  control  siRNA.  After
incubating 48 h, MTT was added and the cells were incubated
for a further 4 h. Formazan crystals that formed were then
dissolved  by  the  addition  of  dimethyl  sulfoxide  (DMSO;
100 μl/well). Absorbance at 570 nm was measured using an
ELISA plate reader (Dynatech Medica, Guernsy, UK) [21].
Cell proliferation was measured by a modified MTT assay on
24, 48, 72, 96, and 120 h. Media were changed on day 3. Each
experiment  was  undertaken  using  three  wells  and  was
performed at least three times.
Cell attachment assay: Ninety-six-well plates coated with
1.25 μg/ml fibronectin in 100 μl of PBS were put into the
incubator overnight at 4 °C. Transfected cells (1×104) were
trypsinized, added to each well, and allowed to attach for 6 h
[22]. The cells were then washed gently twice with PBS, and
150 μl fresh medium was added to each well with MTT. The
absorbance was measured with an ELISA plate reader at 570
nm. We used three different wells to detect the cell attachment
and repeated all the experiments three times.
Cell spreading assay: After transfection, 1×104 cells were
trypsinized  and  added  to  fibronectin-coated  coverslips  in
DMEM and 10% serum at 37 °C for 2 h. After they were
washed with PBS three times, cells were fixed with 4% PFA
in PBS, and then were stained with vimentin and DAPI. Cell
spreading was characterized by the formation of a clearly
defined cytoplasm halo around the cell nucleus, and spreading
was  quantified  by  analysis  of  images  of  four  separate
microscope  fields.  (Leica  Microsystems  GmbH,  Wetzlar,
Germany). Quantitation was performed by measuring the ratio
of cytoplasm area to nucleus area of cells in each field using
Image-Pro Plus software (Media Cybernetics Ins, Bethesda,
MD).  We  used  three  wells  to  detect  cell  spreading  and
repeated all the experiments three times.
Cell migration: Migration assay was performed as described
before [23]. Briefly, 2×104 cells were placed in the upper
chamber in a final volume of 200 μl of serum-free medium.
Next 10% FBS was placed in the bottom chamber for a final
volume of 600 μl. All migration assays were conducted for 4
h at 37 °C. At the end of the assay, the cells were fixed in 4%
PFA and stained with DAPI for 15 min. Remaining cells were
wiped away with a cotton bud, and the membrane was imaged.
The number of cells from five random fields of view was
counted.
Tube formation: The tube formation assay was conducted to
investigate the effect of Robo4 siRNA on RF/6A in vitro.
Aliquots (150 μl) of matrigel solution were poured into the 48
well  plates  (repeated  2  more  times),  and  the  plates  were
Figure 2. Robo4 expression in FVMs from a 60-year-old patient with a 10 year history of diabetes. Immunofluorescent staining showed Robo4-
positive (A, E), CD31-positive (B), and GFAP-positive (F) staining in FVMs. Cell nuclei were stained with DAPI (C,G). The colocalization
of Robo4 and CD31 (D), and Robo4 and GFAP (H) are also shown. Bar graph denote 50 μm.
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1060Figure 3. Robo4 siRNA specifically knocks down Robo4 mRNA and
protein level. A: Robo4 expression in RF/6A and human RPE cells
was significantly knocked down at the mRNA level, measured by
real-time RT–PCR 48 h after transfection. B: The protein expression
of Robo4 protein in RF/6A and human RPE cells was measured by
immunoblotting, normalized to β-actin expression in RF/6A and
RPE cells. One was a representative photograph of the western-blot
analysis  of  Robo4  expression  in  RF/6A;  2  was  a  representative
photograph of the western-blot analysis of Robo4 expression in RPE;
3 was the data of the relative Robo4 protein in the NS, UT and Robo4
siRNA-treated  cells.  Values  are  the  means±SD  of  at  least  three
independent  experiments.  Abbreviations:  control  siRNA  treated
cells  (NS);  untransfected  cells  (UT);  Robo4  siRNA-treated  cells
(Robo4 siRNA). Asterisks denote values signigicantly different from
Robo4 siRNA-treated group compared to NS and UT group (p<0.01).
The pixel intensity of NS was set to 100%.
incubated at 37 °C for 1 h in a 5% CO2 incubator to form a
matrigel gel [21]. RF/6A cells (1×104 per well) treated with
siRNA for 48 h were seeded on the matrigel and cultured in
DMEM  medium.  The  networks  in  matrigel  from  five
randomly chosen fields were counted and photographed under
a microscope.
Flow cytometry: Each of the cell lines (1×106) were seeded in
6-well plates and treated with NS siRNA or Robo4 siRNA
transfection reagent at normoxia or hypoxia for 48 h. Then
dividend into the following groups: NS group at normoxia;
Robo4 siRNA treated at normoxia; NS group with hypoxia;
and Robo4 siRNA with hypoxia. Cells were detached using
EDTA,  washed  in  cold  PBS  (4  °C),  and  stained  with
propidium iodide and Annexin-V-FITC (Becton Dickinson,
Franklin Lakes, NJ) for 15 min at room temperature in the
dark. For cell cycle analysis, cells were treated with the BD
Cycletest™  Plus  DNA  Reagent  Kit  (Becton  Dickinson)
according to the manufacturer’s instructions. Samples were
analyzed using a FACS Caliber cytometer (Becton Dickinson,
Franklin Lakes, NJ). We used three samples in one experiment
and repeated it.
Statistical evaluation: All data were presented as mean±SD
and  evaluated  for  normality  of  distribution.  Statistical
differences  were  evaluated  using  ANOVA  followed  by
Student–Newman–Keuls test for multiple comparisons and
the Student’s t-test for pairwise comparisons. p<0.05 was
considered significant.
RESULTS
Expression  of  Robo4  mRNA  in  FVMs:  RT–PCR  was
performed to verify the expression of Robo4 in the FVMs. As
shown  in  Figure  1,  the  expected  102  bp  PCR  product,
representative of Robo4, was detectable on 1.5% agarose gels
in six (100%) of the six samples of tissues.
Immunohistochemical  detection  of  Robo4  in  FVMs:  To
investigate the presence and distribution of Robo4 in FVMs,
we stained the sections with an anti-Robo4 antibody (Figure
2A),  an  anti-CD31  antibody  (an  endothelial  cell  marker;
Figure 2B), and an anti-GFAP antibody (a glial cell marker;
Figure 2F). Consistent with previous results on the staining
patterns of tumors [5,8], the Robo4 antibody was expressed
in  the  vessels  of  the  FVMs.  We  found  that  Robo4  was
coexpressed  with  GFAP,  a  marker  of  glial  cells,  unlike
previous studies in which Robo4 was not expressed in the
neural tissues of mammals [5,7].
Robo4  siRNA  specifically  knocks  down  Robo4  RNA  and
protein: We first determined the expression of Robo4 in RF/
6A and RPE cells (Figure 3, Figure 4). Robo4 expression in
RF/6A and RPE cells was significantly knocked down at both
the mRNA and protein levels, determined by real-time RT–
PCR and western blot assays, respectively. At the mRNA
level, real-time RT–PCR demonstrated that specific siRNA
depleted Robo4 mRNA levels by 85% and 87% in RF/6A and
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of  Robo4  protein  expression  (p<0.01;  Figure  3A,B).  In
contrast, there was no significant difference between the cells
transfected with control siRNA (NS) and the untransfected
(UT) cells (p>0.05). Immunocytochemical imaging of the
expression of Robo4 in RF/6A and RPE cells confirmed the
knockdown of Robo4 (Figure 4). These results suggest that
we  have  generated  specific  knockdown  reagents  that  can
selectively target Robo4 in both RF/6A and RPE cells.
Transfection of Robo4-specific siRNA is not cytotoxic for RF/
6A or RPE cells: We performed an MTT assay to detect any
transfection-induced  cytotoxicity.  The  mitochondrial
dehydrogenases  of  viable  cells  convert  MTT  to  purple
formazan crystals after incubation for 4 h. The absorbance of
the  solubilized  formazan  product  correlates  with  the  total
metabolic activity of the living cells. There was no significant
difference in the cell viability of the UT, HF (cells treated with
HiPerFect Tranfection Reagent only), and NS groups (p>0.05;
Figure 5).
Robo4 regulates cell attachment, proliferation, spreading,
and migration: In the cell attachment assay, the Robo4 siRNA
treatment reduced the attachment capacity of RF/6A cells by
36% (p<0.05) and of RPE by 35% (p<0.01; Figure 6) after 6
h compared with that of the NS group. The NS and UT groups
were not significantly different in their capacities for cell
attachment  (p>0.05;  data  not  shown).  The  suppression  of
Robo4 reduced cell proliferation by 25% in RF/6A cells at 72
h compared with the proliferation of the NS cells (p<0.01),
and the suppression peaked at 40% on the fourth day (p<0.01).
The  suppression  of  Robo4  in  RPE  cells  reduced  cell
Figure 4. Immunocytochemical assays for Robo4 in RF/6A cells and human RPE cells. The fluorescence, representing the expression of Robo4
in both cell lines, was very strong in NS siRNA-treated cells but was barely detectable in the Robo4-siRNA-treated cells. Abbreviations:
control siRNA treated cells (NS); Robo4 siRNA-treated RF/6A cells (RF/6A siRNA); Robo4 siRNA-treated RPE cells (RPE siRNA). Bar
denote 50 μm.
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cells (p<0.01; Figure 7).
Figure 5. Cytotoxicity caused by the transfection of RF/6A and
human  RPE  cells.  Both  cell  lines  were  transfected  with  control
siRNA or HiPerFect Transfection Reagent and incubated for 48 h.
The inhibition of cellular viability was measured with an MTT assay.
Values are the means±SD of at least three independent experiments.
Abbreviations: untransfected cells (UT); cells treated with HiPerfect
Tranfection Reagent (HF); control siRNA-treated cells (NS); Robo4
siRNA-treated cells (Robo4 siRNA).
Figure 6. Effects of Robo4 on the attachment of RF/6A and RPE
cells.  Cell  attachment  was  assessed  after  6  h  incubation  and
subsequent MTT assay. Values are the means±SD of at least three
independent  experiments.  Asterisks  denote  values  significantly
different from those of cells treated with Robo4 siRNA compared to
NS  siRNA  (p<0.01).  Abbreviations:  control  siRNA-treated  cells
(NS); Robo4 siRNA-treated cells (R4 siRNA). The absorbance of
NS was set to 100%.
In the cell spreading assay, Robo4-knockdown RF/6A
and RPE cells spread less well than the control cells. As shown
in Figure 8, the ratios of the cytoplasm area to nuclear area in
the RF/6A and RPE cells treated with Robo4 siRNA and the
NS group were 23% and 25%, respectively, of the ratio of the
NS group (p<0.01; Figure 8).
Next, we explored the role of Robo4 in the migration of
RF/6A and RPE cells using a modified Boyden chamber in
which the RF/6A and RPE cells migrated through a porous
membrane.  As  shown  in  Figure  9,  the  mean  numbers  of
migrated cells among the Robo4-siRNA-treated RF/6A and
RPE  cells  were  significantly  lower  than  the  number  of
migrated control cells (p<0.05). In contrast, the mean numbers
of migrated cells in the NS and UT groups did not differ
significantly (p>0.05, data not shown).
Suppressing Robo4 disturbs tube formation by RF/6A cells:
In a Matrigel assay, Robo4-knockdown RF/6A cells showed
an  impaired  capacity  to  form  a  regular  network:  fewer
branches were formed and the network was uneven (p<0.05;
Figure 10). There was no significant difference between the
NS and UT groups (data not shown).
Cell cycle and cell apoptosis: As shown in Figure 11, in both
cell  lines,  Robo4-siRNA-treated  cells  exhibited  more  cell
apoptosis than did the NS cells under hypoxic conditions
Figure 7. Effect of Robo4 on the proliferation of RF/6A and human
RPE cells. RF/6A (A) and RPE (B) cell proliferation was measured
with an MTT assay at 24 h, 48 h, 72 h, 96 h, and 120 h. Values are
the means±SD of at least three independent experiments. Asterisks
denote values significantly different from those of cells treated with
Robo4  siRNA  compared  to  NS  siRNA  (p<0.01).  Abbreviations:
control siRNA-treated cells (NS); Robo4 siRNA-treated cells (R4
siRNA).
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1063(p<0.01), whereas under normoxic conditions, there was no
significant difference in apoptosis between the siRNA-treated
and NS groups (data not shown). These results suggest that
Robo4-siRNA-treated  cells  have  a  reduced  tolerance  for
hypoxia,  whereas  Robo4  siRNA  did  not  increase  cell
apoptosis under normal conditions.
The  depletion  of  Robo4  levels  caused  a  significant
accumulation of cells in G0/G1 phase and a marked reduction
in the accumulation of cells in S phase compared with the NS
group. Of the Robo4-siRNA-treated RPE and RF/6A cells,
89.54% and 81.99% were in G1 phase, compared with only
60.17% and 61.91% of the RPE and RF/6A cells, respectively,
in the NS group (p<0.01; Figure 12). Of the Robo4-siRNA-
treated  RPE  and  RF/6A  cells,  4.56%  and  10.08%,
respectively, were in S phase of the cell cycle, compared with
14.98% and 28.47% of the RPE and RF/6A cells, respectively,
in the NS group (p<0.01). A slight difference between the RPE
and  RF/6A  cells  was  observed  in  G2/M  phase:  6.23%  of
Robo4-siRNA-treated RPE cells were in G2/M phase versus
24.85% of NS RPE cells (p<0.01); whereas there was no
Figure  8.  Effects  of  Robo4  on  the
spreading of RF/6A and RPE cells. Cell
spreading was quantified by measuring
the ratio of the cytoplasm area to the
nuclear area in cells in each field. A:
Cell  spreading  of  NS  siRNA-treated
RPE cells. B: Cell spreading of Robo4
siRNA-treated  RPE  cells.  C:  Cell
spreading of NS siRNA-treated RF/6A
cells.  D:  Cell  spreading  of  Robo4
siRNA-treated RF/6A cells. E: The data
of relative ratio of the cytoplasm area to
the nuclear area in NS and Robo4 siRNA
group cells. Values are the means±SD
of  at  least  three  independent
experiments.  Asterisks  denote  values
significantly  different  from  those  of
cells  treated  with  Robo4  siRNA
compared  to  NS  siRNA  (E,  p<0.01).
Abbreviations:  control  siRNA-treated
cells (NS); Robo4 siRNA-treated cells
(R4 siRNA). The ratio of the NS group
was set to 100%. Bar denote 100 μm.
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1064significant difference between Robo4-siRNA-treated RF/6A
cells and NS RF/6A cells (Figure 12).
DISCUSSION
There is increasing evidence that the migration and patterning
of  axons  and  blood  vessels  share  similar  guidance
mechanisms. There are several gene families with established
roles  in  axon  guidance  that  also  control  endothelial  cell
guidance  and  the  angiogenic  sprouting  of  blood  vessels.
Semaphorins, neuropilin, ephrins/ephs, notch, and delta, are
well known as repulsive guidance cues in the nervous system.
However,  they  were  also  demonstrated  to  regulate  blood
vessel branching [22,24,25]. Previous studies of Robo4 have
been performed predominantly in zebrafish and mice [7,9] and
until now, there has been no report of Robo4 expression in
human eye tissue. In this study, we demonstrated for the first
time that Robo4 mRNA is expressed in the FVMs of human
eyes with proliferative diabetic retinopathy. The results of
dual-color  immunofluorecence  analysis  of  the  FVMs  also
showed positive Robo4 staining in the fibrous-like tissue and
the neovascular endothelial cells. The Robo4 staining partially
colocalized  with  GFAP,  which  suggests  that  Robo4
expression may not be confined to the vessels but also in
neural tissues. These observations suggest that Robo4 plays a
role in the formation of FVMs.
Figure  9.  Effect  of  Robo4  on  the
migration  of  RF/6A  and  human  RPE
cells. The migratory activity of both cell
lines was estimated based on the number
of cells that had migrated through the
filter of the chamber. A: Migrated cells
of NS siRNA-treated RF/6A cells. B:
Migrated cells of Robo4 siRNA-treated
RF/6A cells. C: Migrated cells of NS
siRNA-treated RPE cells. D: Migrated
cells of Robo4 siRNA-treated RPE cells.
E: The data of relative migrated cells in
NS  and  Robo4  siRNA  group  cells.
Values  are  the  means±SD  of  at  least
three  independent  experiments.  The
results  showed  that  the  number  of
migrating  cells  in  the  Robo4  siRNA-
treated group was less than in the control
siRNA-treated  group  (E,  p<0.01).
Abbreviations:  control  siRNA  treated
cells (NS);  Robo4 siRNA-treated RF/
6A  cells  (RF/6A  siRNA);  Robo4
siRNA-treated RPE cells (RPE siRNA).
The migrated cells of NS group was set
to 100%.
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1065RNA  interference  mediated  by  siRNA  is  a  powerful
technology, allowing the silencing of mammalian genes with
great specificity and potency. However, nonspecific effects at
both the mRNA and protein levels are known to occur with
siRNA methods and constitute one of the limitations of this
technology  [18].  In  our  study,  we  observed  a  significant
difference between the Robo4-specific siRNA-treated group
and  the  control  siRNA-treated  group,  but  there  were  no
differences between the NS siRNA-treated, HF-treated, and
untreated controls in all assays. These results suggest that the
application of siRNA was experimentally valid and that its
transfection induced no cytotoxicity. In our study, Robo4-
specific siRNA was an effective and specific inhibitor of the
attachment, spreading, migration, and proliferation of both
RF/6A and RPE cells.
Tube  formation  is  one  of  the  main  characteristics  of
retinal and choroid vascular endothelial cells. Tube formation
on Matrigel was used to measure the physiologic effects of
Robo4  on  RF/6A  cells.  Robo4-knockdown  RF/6A  cells
showed  markedly  reduced  tubule  formation  and  failed  to
develop vascular networks on Matrigel. Therefore, Robo4
might play a role in maintaining the tube-forming properties
of RF/6A cells.
Cell migration is another principal indicator of the normal
physiologic functions of endothelial and epithelial cells. RF/
6A and RPE cells transfected with Robo4 siRNA presented
significantly reduced cell migration compared with that of
control cells, whereas overexpressed Robo4 in endothelial
cells blocked the migration of endothelial cells toward VEGF
and  fibroblast  growth  factor  [16].  This  suggests  that  the
Figure 10. Effect of Robo4 on the tube formation of RF/6A cells. Untransfected cells (A), NS siRNA-treated cells (B) and Robo4 siRNA-
treated cells (C) were plated on Matrigel as described in Methods. After 24 h of incubation, UT and NS group cells formed well organized
capillary-like structures (A, B), while Robo4 siRNA group cells ability to organize was severely compromised (C). Values are the means±SD
of at least three independent experiments. Asterisks denote values significantly different from those of cells treated with Robo4 siRNA
compared to NS siRNA and UT group (D, p<0.01). Abbreviations: untransfected cells (UT); control siRNA-treated cells (NS); Robo4 siRNA-
treated cells (Robo4 siRNA) . The number of UT group was set to 100%.
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1066overexpression of Robo4 resulted in a similar phenotype as
that induced by Robo4 siRNA, implying that too little or too
much Robo4 has the same detrimental effect on cell migration
[17], and that appropriate Robo4 expression may sustain the
migration properties of cells.
In this study, we investigated whether Robo4 affects the
proliferation  of  RF/6A  and  RPE  cells.  No  inhibition  was
apparent in the Robo4-siRNA-treated cells for 48 h. The effect
on cell growth was observed in both RF/6A and RPE cells and
Figure 11. Effect of Robo4 on the apoptosis of RF/6A and RPE cells.
A:  Cell  apoptosis  of  NS  siRNA-treated  RF/6A  cells.  B:  Cell
apoptosis of Robo4 siRNA-treated RF/6A cells. C: Cell apoptosis of
NS siRNA-treated RPE cells. D: Cell apoptosis of Robo4 siRNA-
treated RPE cells. E: The data of relative cell apoptosis in NS and
Robo4  siRNA  group  cells.  The  normal  living  cells  (bottom  left
quadrants) showed low annexin V and propidium iodide staining.
The  early  apoptotic  cells  (bottom  right  quadrants)  showed  high
annexin  V  staining  but  low  propidium  iodide  staining.  The  late
apoptotic cells (top right quadrants) showed high annexin V and
propidium iodide staining. The percentages of cells in the quadrants
are indicated within the quadrant of all panels. Representative results
of three separate experiments are shown. Values are the means±SD
of at least three independent experiments. Asterisks denote values
signigicantly different from those of cells treated with Robo4 siRNA
compared to NS siRNA and UT group (E, p<0.01).
is probably attributable to G1/S cell-cycle arrest. The role of
Figure 12. Effect of Robo4 on the cell cycles of RF/6A and human
RPE cells. A: Cell cycle of NS siRNA-treated RPE cells. B: Cell
cycle  of  Robo4  siRNA-treated  RPE  cells.  C:  Cell  cycle  of  NS
siRNA-treated RF/6A cells. D: Cell cycle of Robo4 siRNA-treated
RF/6A cells. E: The data of RPE cell cycle distribution of NS and
Robo4 siRNA group cells. F: was the data of RF/6A cell cycle
distribution of NS and Robo4 siRNA group cells. Flow cytometric
analysis demonstrated the effects of Robo4 on the cell cycle. The x-
axis represents the fluorescence intensity on a logarithmic scale and
the y-axis represents the number of events. The results show that the
fraction of G1-phase cells increased and the proportion of S-phase
cells decreased in the RF/6A and RPE cells after knockdown of
Robo4.  Values  are  the  means±SD  of  at  least  three  independent
experiments. The proportion of G0/G1, G2, and S phase cells was
decreased  in  Robo4  siRNA-treated  RPE  cells  compared  to  NS
siRNA-treated RPE cells (E, *p<0.01). The proportion of G0/G1 and
S phase cells was decreased in Robo4 siRNA-treated RF/6A cells
compared  to  NS  siRNA-treated  RF/6A  cells  (F,  *p<0.01).
Abbreviations: control siRNA-treated cells (NS); Robo4 siRNA-
treated cells (R4 siRNA). The cell cycle of NS was set to 100%.
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1067Robo4 on the two cell lines was a little different at G2/M phase:
Robo4 siRNA reduced the numbers of RPE cells in G2/M
phase but had no effect on the RF/6A cells. This difference
between the two cell types may be attributable to species or
cell-type differences: RF/6A is an endothelial cell line, and
RPE is an epithelial cell line.
In this study, we exposed RF/6A and RPE cells to hypoxic
conditions  in  vitro  to  mimic  the  hypoxia  experienced  by
endothelial and epithelial cells in ischemic retinal and choroid
diseases in vivo. We found that under normoxic conditions,
there was no significant difference in cell apoptosis between
the  Robo4-siRNA-treated  and  NS  groups,  whereas  under
hypoxic conditions, more apoptotic cells were detected in the
Robo4-siRNA-treated  group  than  in  the  NS  group.  These
results suggest that Robo4 does not affect cell apoptosis under
normal  conditions  but  increases  cell  tolerance  of  hypoxic
conditions. This is consistent with a previous study in which
a model of retinopathy of prematurity in Robo4AP/AP mice
showed increased angiogenesis and vascular leakage [10].
In summary, our study indicates that Robo4 may play a
role in the formation of FVMs. Silencing Robo4 expression
in  RF/6A  and  RPE  cells  inhibited  their  proliferation,
migration,  spreading,  tube  formation,  and  tolerance  of
hypoxia, and thus may be involved in retina vasculogenesis
and angiogenesis.
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